Kornimate/medical-research-clean huggingface dataset:
a prospective study comparing the mifne approach of treating childhood autism with routine standard treatment

Conditions: Child Development Disorders, Pervasive

Summary: the current study aims at comparing outcomes achieved using the mifne approach of treating autistic children with results obtained when routine standard treatment is used. a prospective comparative study will be performed comparing the results of 12 children treated at mifne with 12 children treated with treatment as usual. a child and adolescent psychiatrist using the autism diagnostic interview-revised (adi-r) and the autism diagnostic observation schedule-generic (ados-g) will make the diagnostic assessment and a developmental psychologist will make the developmental and psychological assessments using the vineland adaptive behavior scales-revised and the bayley scales of infant development (bsid ii) before the child enters the study. each child will be reassessed following completion of the mifne intervention, at three and at six months after commencement of treatment. the control child will also be reassessed at three and at six months after commencement of a therapeutic intervention.


Eligibility criteria:
inclusion criteria: * all children between the ages of 2-5 years who meet diagnostic criteria for autism or pervasive developmental disorder by dsm iv criteria who are referred for treatment at mifne for the treatment group. * the control group will consist of children meeting the same criteria who are referred to schneider children's medical center of israel (scmci). matching will be for age, sex, ethnicity, socioeconomic status, iq, language development and diagnosis. exclusion criteria: * all referred children who do not meet criteria for autism or pdd or do not understand hebrew.

Keywords: autism spectrum disorder autistic disorder pervasive developmental disorder
aquatic exercise study for breast cancer patients with lymphedema

Conditions: Lymphedema

Summary: the purpose of this study is to determine what effects aquatic exercise has on participants with lymphedema.

this pilot study will examine the effectiveness of aquatic exercise in reducing lymphedema. the study is designed for breast cancer patients who have developed lymphedema following cancer treatment. potential study participants should have explored conventional treatments such as decongestive therapy and lymph drainage massage before joining the study. there are two groups that the participants may choose from until enrollment for the group has reached its capacity.the active arm of the study will attend 12 one-hour aquatic exercise classes and classes will be held in an indoor heated pool. there is no cost to the participants.both the active arm and the control group (not attending aquatic exercise classes) will have 3 measurement assessments that will compare the circumference and volumetric measurement of arms, as well as height, weight and body mass index (bmi). both group will fill out a program questionnaire. quality of life survey taken at baseline, week 6, month 6 and 12 will be compared. a follow up questionnaire will be completed at 6 and 12 month intervals, and annually for five years.

Eligibility criteria:
inclusion criteria: * breast cancer patients with lymphedema * patients must have received standard lymphedema treatment (complete decongestive therapy) prior to participating in the study. * patients undergoing treatment will require written permission from their physician * complete an assessment by a licensed physical therapist before beginning the exercise program * patients must sign a consent form to participate exclusion criteria: * patients undergoing treatment without physician's written permission * patients with health problems that contraindicate exercise * patients are not eligible if the physical therapy assessment identifies a contraindication to participation inclusion of women and minorities: - men, women and minorities with breast cancer related lymphedema are eligible

Keywords: lymphedema aquatic exercise breast cancer
the effects of external counter pulsation therapy on circulating endothelial progenitor cells

Conditions: Coronary Artery Disease

Summary: the objectives of the study are to test the hypothesis that external counter pulsation therapy (ecpt) provides clinical benefit by improving the number and function of endothelial progenitor cells (epcs) in peripheral blood of patients with angina pectoris.

ecpt is a non-invasive approach for increasing blood flow to the heart in patients with myocardial ischemia. ecpt produces beneficial effects in coronary artery disease (cad) patients. however, the exact mechanisms of ecpt action are not defined yet. evidence has now accumulated that bone marrow-derived cells with angiogenic capability, termed epcs, circulate in the blood of adults. epcs possess the ability to home to sites of ischemia and contribute to neoangiogenesis. we prospectively study cad patients \[canadian cardiovascular society (ccs) angina class ii-iv\], before and after ecpt , and compare them with age- and sex-matched controls. peripheral blood cd34+ cells, epcs (cd34/vegfr2+ cells), epc colony forming units (cfus) and brachial artery endothelial function is assessed prior to and after ecpt. percent improvement in endothelium-dependent brachial artery flow-mediated dilatation (%fmd) is assessed using high-resolution ultrasound.

Eligibility criteria:
inclusion criteria: * coronary artery disease * ccs angina class ii-iv exclusion criteria: * aortic regurgitation * acute myocardial infarction \<3 months * systemic hypertension \>180/110 mm * atrial fibrillation * deep vein thrombosis * phlebitis and hemorrhagic diathesis * pregnancy * abdominal aortic aneurism * metastatic tumor

Keywords: ecpt, endothelial progenitor cells
comparison of postoperative analgesic efficacy of the erector spina plane block and quadratus lumborum block in open nephrectomy: a prospective randomized clinical study

Conditions: Renal Cell Carcinoma

Summary: patients who will undergo elective open nephrectomy will be divided into three groups; the control (pca), the erector spina plane block, and the quadratus lumborum block. after standard anesthesia induction and monitorization then bispectral index monitoring will be applied to all patients. anesthesia will be maintained using sevoflurane in a mixture of oxygen and air. continuous remifentanil infusion will be used for analgesia. then patient's numeric rating scales and morphine pca consumptions will be recorded for one day.

patients who will undergo elective open nephrectomy will be divided into three groups; the control (pca), the erector spina plane block and the quadratus lumborum block. after standard anesthesia induction and monitorization then bispectral index monitoring will be applied to all patients. anesthesia will be maintained using sevoflurane in a mixture of oxygen and air. continious remifentanil infusion will be used for analgesia. then patient's numeric rating scales and morphine pca consumptions will be recorded for one day.

Eligibility criteria:
inclusion criteria: * asa 1-3 * open nephrectomy elective patients * bmi\<35 exclusion criteria: * asa 4-5-6 * laparoscopic nephrectomy * infection at the block side * coagulation disorder * bmi\>35

Keywords: erector spina plane block quadratus lumborum block patient controlled analgesia nephrectomy analgesia
predicative value of multimodal mri in moyamoya disease

Conditions: Moyamoya Disease; Magnetic Resonance Imaging

Summary: moyamoya disease (mmd) is a nonatherosclerotic cerebrovascular abnormality, characterized by a progressive stenosis or occlusion of the intracranial internal carotid arteries (icas) and their proximal branches, with subsequent formation of collateral vessels ("puff of smoke"). in some cases, the posterior circulation can also be involved. mmd has been discovered around the world, but asians carry the most possibility to develop this disease. current treatment designed to prevent strokes by improving blood flow to the affected cerebral hemisphere including medical therapy and surgery. in particular, surgery included two general methods: direct and indirect revascularization. compared with direct bypass, indirect procedures are more technically accessible and may reduce the possibility of complications, such as hyperperfusion. in addition, magnetic resonance imaging (mri) with derived parameters have shown great potential in evaluating perfusion in patients, and could possibly predict surgical outcome. however, there is still lack of evidence of the predictive value of mri in evaluating clinical and angiography improvement in patients with mmd.

imaging protocols: 3d tof 3slab; swan; 3d asl 2.0s; t1; t2; t2 flair; dwi; tasl 2.0s; dce; apt-cest imaging evaluation: 1. transfer contrast volume value measured by dce; 2. asl shows cbf in associated regions; 3. stoke area measured by dwi and flair; 4. ph values reflected by apt-cest. treatment: surgery-indirect revascularization follow-up: baseline (mri+dsa); 3-months follow-up (mri); 6-months follow-up (mri+dsa)

Eligibility criteria:
inclusion criteria: * dsa/mra shows stenosis or occlusion in the distal internal carotid artery or the proximal portion of anterior/middle cerebral artery; * abnormal vascular network appeared in the brain; * with the onset of cerebral ischemia/hemorrhage/tia; * no cerebral infarction or cerebral hemorrhage occurred within the last month; * all mri examination performed according to study protocol; * signed informed consent obtained from the patient or patient's legally authorized representative; * having complete medical history and clinical follow up; * imaging data can be processed. exclusion criteria: * patients with moyamoya syndrome secondary to systemic diseases such as arteriosclerosis, sickle cell anemia, radiation therapy, etc.; * patients with severe mental disorders such as psychosis, liver and kidney dysfunction, poor blood pressure or blood glucose control, severe depression and substance abuse, low iq, and acute phase of severe stroke with definite limb dysfunction should also be excluded. * pregnancy
a multicenter clinical study of rtms for parkinson's disease

Conditions: Parkinson's Disease

Summary: through rtms, motor dysfunction and non-motor dysfunction of pd patients can be improved, working and living ability and quality of life of patients can be improved, and social burden and family burden can be reduced.

according to the inclusion criteria, a total of 200 patients with parkinson's disease were planned to be enrolled in each center, and randomly divided into control group (conventional treatment) and observation group (conventional treatment +rtms) for a treatment cycle of 4 weeks. they were followed up for 3 months before treatment, 2 weeks and 4 weeks, respectively, after treatment, to evaluate the efficacy and function. the unified parkinson's disease rating scale (updrs) was used. cognitive function assessment monteller cognitive assessment scale (moca); barthel index for daily living activities; depression assessment hamilton depression scale (hamd); hamilton anxiety scale (hama); sleep assessment pd sleep scale (pdss); pain assessment king parkinson's pain assessment (kpps) and adverse events were recorded.

Eligibility criteria:
inclusion criteria: * hoehn-yahr classification is between 1 and 2； * have a primary school education or above and can read the scale used in this study; * moca score between 20 and 24, mild cognitive impairment ; * aged between 30 and 80, regardless of gender； * voluntarily participate and sign informed consent. exclusion criteria: * patients with cerebrovascular accident, craniocerebral injury and other diseases affecting muscle tension; * patients with serious mental disorders and cognitive disorders who cannot cooperate with assessment; * patients with severe liver, kidney, heart dysfunction and severe physical disorders; * implanted devices such as pacemakers are installed inside the body; * drug-induced parkinson's syndrome or parkinson's superposition syndrome; * have a history of epilepsy; * women during pregnancy and breastfeeding.

Keywords: parkinson's disease repetitive transcranial magnetic stimulation(rtms) unified parkinson's disease rating scale (updrs) montreal cognitive assessment scale (moca) activity of daily living(adl) pd sleep scale (pdss) king's parkinson's pain assessment (kpps)
open, pharmacokinetic study of caspofungin acetate in immunocompromised young children with febrile neutropenia (0991-042)

Conditions: Fungal Infection

Summary: this is an open-label study of mk0991 in children between 3 to 24 months of age with new onset fever and neutropenia. the purpose of the study is to investigate plasma drug levels of caspofungin.


Eligibility criteria:
inclusion criteria: * patient is 3 to 24 months of age with one or more of the following conditions: * leukemia, lymphoma, or other cancers * bone marrow or peripheral stem transplantation * high dose chemotherapy leading to a decrease in white blood cells * aplastic anemia * patient has an absolute neutrophil count \ 38 degreesc (oral or oral equivalent) within 72 hours of screening. exclusion criteria: * patient is \ 24 months of age at the time of study drug administration * patient has proven or probable invasive fungal infection at the time of enrollment * patient has certain blood clotting or liver function abnormalities * patient is hemodynamically unstable, exhibits hemodynamic compromise or is not expected to survive at least 5 days * patient is taking rifampin, cyclosporin a, phenytoin, carbamazepine, or phenobarbital.
laser assisted nonsurgical periodontal treatment

Conditions: Chronic Periodontitis

Summary: periodontitis is a chronic inflammatory disease caused by mixed infections with the subgingival microbiota being organized as a biofilm that, if untreated, may result in breakdown of the periodontal tissues in susceptible individuals. evidence from intervention studies shows that mechanical root debridement significantly improves periodontal health by halting the progression of periodontal tissue breakdown. in order to improve effectiveness and efficacy of the removal of the subgingival biofilm, er:yag laser therapy has recently been recommended as an alternative to conventional scaling procedures.


Eligibility criteria:
inclusion criteria: greater than 25 years, clinical diagnosis of moderate to advanced chronic periodontitis, pocket depth ≥ 5 mm or clinic attachment level ≥ 4 mm at least in two interproximal areas (not on the same tooth), along with very good oral hygiene scores (gi≤1and pi≤1), at least 4 teeth in each quadrant, teeth with subgingival plaque sample is collected has no restoration or prothesis exclusion criteria: periodontal treatment ( root planning or surgical periodontal treatment) had done before, systemic disease that could influence the outcome of periodontal therapy, prophylaxis regime mandatory during periodontal treatment, use of any drug that could influence the outcome of periodontal therapy, use of antibiotics within the last 3 months, use of anti-inflammatory drugs within the last 3 months, use of removable prothesis pregnancy, lactation or use of hormone contraceptives, smoking

Keywords: chronic periodontitis, laser
effect of quadro-iliac plane block on recovery after total hip arthroplasty

Conditions: Postoperative Pain

Summary: total hip arthroplasty is a widely performed surgical procedure in the elderly population, aiming to relieve hip joint pain and restore function. total hip arthroplasty is among the most critical surgical procedures in terms of morbidity and mortality within this demographic. to mitigate opioid-related adverse effects in this patient group, novel analgesic methods are needed. regional anesthesia techniques used for postoperative pain management include epidural analgesia, lumbar plexus block, fascia iliaca block, femoral and obturator nerve blocks, and sacral erector spinae plane block. however, these procedures may result in complications such as epidural hematoma, postoperative headache, prolonged motor block, and extended hospital stay.

total hip arthroplasty is a widely performed surgical procedure in the elderly population, aiming to relieve hip joint pain and restore function. total hip arthroplasty is among the most critical surgical procedures in terms of morbidity and mortality within this demographic. to mitigate opioid-related adverse effects in this patient group, novel analgesic methods are needed. regional anesthesia techniques used for postoperative pain management include epidural analgesia, lumbar plexus block, fascia iliaca block, femoral and obturator nerve blocks, and sacral erector spinae plane block. however, these procedures may result in complications such as epidural hematoma, postoperative headache, prolonged motor block, and extended hospital stay. recently, tulgar et al. introduced a novel fascial plane block called the "quadro-iliac plane block". this block is performed in the quadro-iliac plane, located between the inner surface of the iliac crest and the posterior surface of the quadratus lumborum muscle. in their study, tulgar et al. bilaterally injected 40 ml of methylene blue into the quadro-iliac plane, observing widespread dye distribution along the posterior and anterior surfaces of the quadratus lumborum muscle, transversalis fascia, ilioinguinal, iliohypogastric, subcostal, and genitofemoral nerves, as well as the lumbar plexus. based on these findings, quadro-iliac plane block has been proposed as a potentially effective technique for managing acute or chronic pain in the lumbosacral, abdominal, and hip regions. however, apart from a few case reports involving lumbar spine surgery and kidney transplantation, evidence regarding the efficacy of quadro-iliac plane block remains limited.

Eligibility criteria:
inclusion criteria: * unilateral tha. * spinal anesthesia. * age 18-85 years. * asa classification i-iv. exclusion criteria: * patients who declined consent. * contraindications to regional anesthesia. * coagulation disorders. * infections at the block site. * emergency surgeries.
diabetic kidney disease: influence of exercise therapy on physical and vascular function.

Conditions: Focus Type 2 Diabetes Related Chronic Kidney Disease

Summary: the general objective is to investigate the effect of a 12 week walking exercise program on vascular endothelial function, arterial stiffness/compliance, and vascular health biomarkers in men and women with pre-dialysis type 2 diabetic kidney disease (dkd).


Eligibility criteria:
inclusion criteria: * • an individual must be \>18 years of age have diagnosed type 2 diabetic mellitus by one of the following criteria: o treated with diet, diet plus oral hypoglycemic agents (for at least one year), or insulin preceded by treatment with oral agents (for at least one year). if treated with insulin, the onset of diabetes must have occurred after age of 40 and the body mass index must be \>25kg/m2 at the time of diagnosis. diagnosed kidney attributed to diabetes by one of the following criteria:3 * macroalbuminuria (acr \>300mg/g, or) * microalbuminuria (acr between 30-300 mg/g) or in the presence of diabetic retinopathy (although is recognized that about 1/3 of type 2 diabetics do not have retinopathy by fundoscopic exam). * an elevated acr should have been confirmed in the absence of urinary tract infections with 2 additional first-void specimens collected over 3-6 months. * at least 2 of 3 samples should fall within the range of micro or macroalbuminuria. * an estimated glomerular filtration rate (gfr) of between 90 ml/min and 30 ml/min measured by (gfr (ml/min/1.73 m2) = 186 x (scr)-1.154 x (age)-0.203 x (0.742 if female) x (1.210 if african-american) (conventional units). * individuals must be able to provide informed consent * perform walking exercise testing on a treadmill * be able to participate in a 12-week supervised exercise program. exclusion criteria: * • patients are currently exercising * requiring dialysis * have an hematocrit \<30% * uncontrolled hypertension (\>200/100mmhg) * peripheral vascular disease. * an inability to understand english or give consent. other exclusion criteria are: any contraindications to exercise testing or training as indicated by the american college of sports medicine guidelines such as: unstable coronary heart disease and symptomatic heart failure, exercise capacity limited by health problems such as angina, severe arthritis, or extreme dyspnea on exertion, progressive neuromuscular disease, pulmonary disease., or having undergone a coronary revascularization within the past 6 months prior to enrollment.

Keywords: exercise diabetic kidney disease vascular function physical function
randomized, double-blind study in participants with dee to assess efficacy, safety, tolerability, and pk of relutrigine

Conditions: Developmental and Epileptic Encephalopathy 1

Summary: a phase 3, randomized, multi-center, double-blind, placebo-controlled clinical trial to evaluate the efficacy, safety, tolerability, and pharmacokinetics of relutrigine in participants with developmental and epileptic encephalopathies followed by an open-label extension


Eligibility criteria:
inclusion criteria: * has a documented diagnosis of a developmental and epileptic encephalopathy. * onset of seizures \<12 years old. * has a weight \>7 kg at the time of signing consent/assent. exclusion criteria: * has a history of left bundle branch block, arrhythmias, brugada syndrome, congenital heart disease, familial short qt syndrome, or family history of sudden death or ventricular arrhythmias, including idiopathic ventricular fibrillation. * had 2 or more episodes of convulsive status epilepticus requiring hospitalization and intubation in the 6 months prior to screening. * has an abnormal ecg reading, including a qt interval corrected for heart rate using bazett's method (qtcb) \ 450 ms (males), or \ 460 ms (females) at screening and/or on day 1. * any nerve stimulation must have been placed at least 3 months prior to screening with at least 1 month of stable settings prior to screening. * has received any other experimental or investigational drug, device, or other therapy within 30 days or 5 half-lives (whichever is longer) prior to screening, including any prior use of gene therapy. * is currently pregnant or breastfeeding or is planning to become pregnant during the clinical trial or within 5 half-lives of the last study drug dose.

Keywords: dee developmental and epileptic encephalopathy epilepsy
radiofrequency ablation for hepatocellular carcinoma using octopus mp electrodes

Conditions: Hepatocellular Carcinoma

Summary: this study is to investigate the therapeutic effect and treatment results of radiofrequency ablation using the octopus mp electrode capable of temperature monitoring and drug injection and a variable-length electrode for treatment of small hepatocellular carcinomas (≤ 3cm).


Eligibility criteria:
inclusion criteria: * child-pugh class a or b * chronic hepatitis b or chronic hepatitis c or liver cirrhosis * presence of hepatocellular carcinoma (hcc) after confirmed by pathology or imaging studies including contrast enhanced computed tomography (ct) or magnetic resonance imaging (mri) according to the korean liver cancer study group (klcsg)-national cancer center (ncc) korea practice guidelines. * up to 3 lesions, each greater than less than or equal to 3 cm at the time of locoregional treatment. exclusion criteria: * number of recurrent hccs, more than 3 * largest hcc size over 3 cm * presence of vascular invasion by hcc * platelet count less than 40,000 per mm3 or international normalized ratio (inr) prolongation over 50% * presence of extrahepatic metastasis
long-term specified drug use-results survey for xtandi capsule

Conditions: Castration-resistant Prostate Cancer

Summary: the purpose of this study is to confirm the long term safety and efficacy of enzalutamide in patients.


Eligibility criteria:
inclusion criteria: * no history of treatment with enzalutamide exclusion criteria: -

Keywords: xtandi mdv3100 long term use enzalutamide